ArticleViruses2021
Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Posttranslational modifications of heterologous proteins expressed in Nicotiana benthamiana.Plant biotechnology journal · 2026Review
- Architects of folding, editors of immunity: the strategic use ofFrontiers in immunology · 2026Article
- Plant production of recombinant antigens containing the receptor binding domain (RBD) of two SARS-CoV-2 variants.Biotechnology letters · 2024Article
- In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.Plant biotechnology journal · 2023Article
- Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19.Life (Basel, Switzerland) · 2023Review
- A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters.Frontiers in plant science · 2023Article
- Performance of plant-produced RBDs as SARS-CoV-2 diagnostic reagents: a tale of two plant platforms.Frontiers in plant science · 2023Article
- SARS-CoV-2 spike protein S1 subunit induces potent neutralizing responses in mice and is effective against Delta and Omicron variants.Frontiers in plant science · 2023Article
- Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants.Frontiers in plant science · 2023Article
- High-Yield Production of Chimeric Hepatitis E Virus-Like Particles Bearing the M2e Influenza Epitope and Receptor Binding Domain of SARS-CoV-2 in Plants Using Viral Vectors.International journal of molecular sciences · 2022Article
- Rapid Transient Expression of Receptor-Binding Domain of SARS-CoV-2 and the Conserved M2e Peptide of Influenza A Virus Linked to Flagellin inPlants (Basel, Switzerland) · 2022Article
- HIV and SARS-CoV-2 Pathogenesis and Vaccine Development.Viruses · 2022Article
- Plant-Produced S1 Subunit Protein of SARS-CoV-2 Elicits Immunogenic Responses in Mice.Vaccines · 2022Article
- Investigation of theMolecules (Basel, Switzerland) · 2022Article
- Theaflavin 3-gallate inhibits the main protease (MScientific reports · 2022Article
- Transient Expression of Glycosylated SARS-CoV-2 Antigens inPlants (Basel, Switzerland) · 2022Review
- Production of the SARS-CoV-2 Spike protein and its Receptor Binding Domain in plant cell suspension cultures.Frontiers in plant science · 2022Article
- Computer-Based Immunoinformatic Analysis to Predict Candidate T-Cell Epitopes for SARS-CoV-2 Vaccine Design.Frontiers in immunology · 2022Article
- SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines.Journal of King Saud University. Science · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
The COVID-19 pandemic, caused by SARS-CoV-2, has rapidly spread to more than 222 countries and has put global public health at high risk. The world urgently needs cost-effective and safe SARS-CoV-2 vaccines, antiviral, and therapeutic drugs to control it. In this study, we engineered the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein and produced it in the plant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.